PR Newswire

First patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trial

Written by PR Newswire

Plus, Actinogen receives approval of its application for a UK Innovation Passport as part of the Innovative Licensing and Access Pathway (ILAP) for Xanamem in the treatment of Alzheimer's disease

Enrolment in XanaCIDD phase 2a trial of cognitive impairment and depression has surpassed 90%

SYDNEY, April 15, 2024 /PRNewswire/ -- Actinogen Medical...

First patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trial

Leading laundry ideas to love

Electric Vehicle Charger and EV Charger …

McHitch and Roo Systems: Revolutionising…

Designing for Health: The Importance of …

How Mining Hose Selection Can Improve Ma…

The Bulletin Magazine

The Essential Bathroom Renovation Supplies Checklist Before You Start

Pull Up Stands: A Convenient Display Option for Events and Promotions

How Mining Hose Selection Can Improve Material Transfer Systems

Electric Sliding Door: What to Consider Before Choosing One

What Is Included in a Professional Roof Repair Service on the Gold Coast?

The Unglamorous Baby Buys That Save Australian Parents the Most Time

Cryptocurrency Trading in 2026_ Why Regulated Education Is the New Standard

How Mining Hose Routing Can Influence Wear and Transfer Efficiency

Cryotherapy in Melbourne: What Skin Lesions Can Be Treated with Targeted Cold Therapy?

10 Restaurants in Cranbourne You Need to Try Before 2027

ZOLL Defibrillators: Why They're a Leading Choice for Businesses, Warehouses, and Healthcare Settings

How Property Maintenance Issues Can Affect Commercial Tenancies